Showing results (81-90 of 245) with videos related to
Sort By:
Pageof 25
Molecular Cancer Therapeutics|November 18, 2003
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance proteinTracy A Brooks, Hans Minderman, Kieran L O'Loughlin, et al.Leukemia Research|May 13, 2008
Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family membersAruna Padmanabhan, Julie A Baker, Gary Zirpoli, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 18, 2007
Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemiaJoli R Weiss, Maria R Baer, Christine B Ambrosone, et al.Cancer Chemotherapy and Pharmacology|October 13, 2006
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteinsAttaphol Pawarode, Suneet Shukla, Hans Minderman, et al.Journal of Oncology Practice|January 8, 2015
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part DAmy J Davidoff, Franklin B Hendrick, Amer M Zeidan, et al.Blood|November 24, 2001
Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemiaUdomsak Bunworasate, Hilal Arnouk, Hans Minderman, et al.Molecular Cancer Research : MCR|April 2, 2015
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated LeukemiasNidal Muvarak, Shannon Kelley, Carine Robert, et al.Haematologica|January 3, 2012
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromesAmy J Davidoff, Sheila Weiss Smith, Maria R Baer, et al.Molecular Cancer Therapeutics|June 16, 2005
In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cellsHans Minderman, Jeffrey M Conroy, Kieran L O'Loughlin, et al.Molecular Cancer Therapeutics|July 11, 2012
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, et al.Pageof 25